December 11, 2025 | Pharmaphorum
Discover Jim Sage’s insights on leadership, industry challenges, and the transformative impact of data, technology, and patient-centric innovation in his latest pharmaphorum “12 Questions” interview.

We’re pleased to share that Jim Sage, Global CEO and President of Inizio Engage, has been featured in pharmaphorum’s latest “12 Questions” interview series.
In the conversation, Jim reflects on his career across international markets, his motivations as a leader, and the experiences that have shaped his approach to building high-performing teams. He also explores some of the most pressing challenges facing the pharmaceutical industry today, including pricing pressures, launch performance, and the need for new reimbursement models.
Jim highlights how data, technology, and AI are already transforming the way organisations operate, and discusses the growing importance of patient-centric approaches, from HUB services to personalised support throughout the treatment journey.
This content was provided by Inizio
Latest Content from Inizio
As the global hematology community prepares for the 67th ASH® Annual Meeting and Exposition, Inizio experts share their perspectives on what’s driving the field forward – and how pharma companies…
At Inizio Medical, we believe AI isn’t replacing Medical Affairs — it’s redefining what’s possible. Our platform, iON.AI™, enhances human expertise, streamlines complex workflows, and strengthens strategic impact through seamless…
Discover how Inizio experts are shaping the future of obesity care—where science, strategy, and innovation unite to advance cardiometabolic health and drive real-world impact.
At Fierce Pharma Week, Inizio revealed how the fusion of human expertise and purposeful AI is reshaping pharma communications and driving real-world impact—discover how this human-centered innovation is defining the…
Inizio is leading the way in Intelligent Commercialization™ by uniting proprietary AI-powered platforms, deep scientific expertise, and proven governance to unlock measurable, lasting value at every stage of commercialization.
We’re attending Obesity Week 2025, the world’s leading event dedicated to obesity research and care, to showcase how our integrated expertise is advancing progress in obesity and cardiometabolic health.
Inizio has appointed Mary-Kate McGarry as Chief Strategy & Innovation Officer and Gavin McShera as Chief Information Officer, strengthening its executive leadership to drive innovation, digital transformation, and Intelligent Commercialization™…
Inizio has been named a finalist in six categories at the 2025 PM360 Trailblazer Awards, recognizing its teams’ excellence in AI, data analytics, education, patient engagement, and industry partnership across…
Inizio experts contribute to Forbes’ Voices of Oncology, highlighting our commitment to driving innovation in cancer care through advanced data analytics, cross-sector collaboration, and real-world impact for patients.
Inizio have appointed Ryan Quigley as Chief Executive Officer, effective 9 September 2025. Paul Taaffe will remain closely involved with the company as an Advisor and board member going forward. …
